MedTrace Logo

Novel Nutrition Solutions for Sarcopenia

NCT03429491 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2019-04-18

No results posted yet for this study

Summary

This study will examine the effect of leucine-enriched protein supplementation, alone and in combination with long chain n-3 polyunsaturated fatty acids (LC n-3 PUFA), on muscle mass and function in older adults at risk of sarcopenia.

The investigators hypothesize that LC n-3 PUFA supplementation will further enhance the efficacy of the leucine-enriched protein.

Conditions

Interventions

DIETARY_SUPPLEMENT

Placebo

Protein-free, LC n-3 PUFA-free juice based supplement

DIETARY_SUPPLEMENT

Leucine-enriched protein

Leucine-enriched whey protein

DIETARY_SUPPLEMENT

LC n-3 PUFA

LC n-3 PUFA

Sponsors & Collaborators

  • University College Dublin

    lead OTHER

Principal Investigators

  • Helen Roche, PhD · University College Dublin

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-06-01
Primary Completion
2018-12-21
Completion
2018-12-21

Countries

  • Ireland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03429491 on ClinicalTrials.gov